Akums Drugs & Pharmaceuticals Ltd

Akums Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Akums Drugs & Pharmaceuticals Ltd

₹ 589 0.38%
13 Dec - close price
Company website BSE: 544222 NSE: AKUMS
About

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Key Points

Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.

Website BSE NSE
  • Market Cap ₹ 9,275 Cr.
  • Current Price ₹ 589
  • High / Low ₹ 1,176 / 527
  • Stock P/E
  • Book Value ₹ 180
  • Dividend Yield 0.00 %
  • ROCE 2.40 %
  • ROE -3.57 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Stock is trading at 3.27 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -6.60% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of Nifty MidSmallcap 400 Nifty Total Market Nifty Smallcap 250 Nifty 500 Nifty 500 Multicap 50:25:25

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Mar 2024 Jun 2024 Sep 2024
970 1,181 944 1,019 1,033
1,095 1,029 941 891 912
Operating Profit -125 152 3 128 121
OPM % -13% 13% 0% 13% 12%
8 -21 10 7 17
Interest 12 14 12 13 12
Depreciation 30 30 34 34 35
Profit before tax -159 87 -33 87 92
Tax % 18% 62% 20% 30% 27%
-187 33 -39 61 67
EPS in Rs -13.16 2.22 -2.89 4.08 4.14
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,464 1,651 2,414 2,723 3,672 3,655 4,178
1,340 1,507 2,240 2,485 3,761 3,361 4,055
Operating Profit 124 144 174 237 -89 294 123
OPM % 8% 9% 7% 9% -2% 8% 3%
6 6 26 12 7 15 8
Interest 23 22 20 7 17 46 51
Depreciation 31 38 67 70 95 113 126
Profit before tax 77 89 114 172 -193 150 -45
Tax % 51% 50% 62% 28% 30% 35% -102%
43 61 44 123 -251 98 1
EPS in Rs 366.55 523.23 335.61 949.10 -35.30 6.63 -0.28
Dividend Payout % 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 15%
TTM: 14%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -120%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: -7%
Last Year: -4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 1 1 1 1 14 29 29 31
Reserves 493 628 721 884 608 689 681 2,803
255 213 175 97 395 619 565 530
293 318 1,140 1,170 2,033 1,905 2,229 906
Total Liabilities 1,042 1,161 2,037 2,152 3,050 3,241 3,504 4,270
444 501 645 834 1,021 1,097 1,191 1,257
CWIP 0 11 57 87 31 103 195 164
Investments 0 18 6 19 0 0 0 0
598 632 1,329 1,212 1,998 2,041 2,118 2,850
Total Assets 1,042 1,161 2,037 2,152 3,050 3,241 3,504 4,270

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
72 89 28 135 32 177 498
-150 -123 -190 -109 -235 -305 -331
66 37 233 -95 236 125 -108
Net Cash Flow -11 4 71 -70 33 -4 59

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 68 57 88 71 88 84 73
Inventory Days 114 115 99 93 112 117 90
Days Payable 67 60 105 74 92 91 76
Cash Conversion Cycle 115 112 82 90 109 111 87
Working Capital Days 78 73 75 77 84 89 76
ROCE % 14% 20% -16% 22% 2%

Shareholding Pattern

Numbers in percentages

Sep 2024
75.26%
7.34%
7.53%
7.14%
2.73%
No. of Shareholders 57,531

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls